Insuline Asparte (Levure/Saccharomyces Cerevisiae) shortage — NL supply status & alternatives

Insuline Asparte (Levure/Saccharomyces Cerevisiae)

—

In supply · Australia

Fiasp Pumpcart

In supply · 🇦🇺 Australia · short in🇫🇷 FR🇳🇱 NL

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Insuline Asparte (Levure/Saccharomyces Cerevisiae)

Brand names	Fiasp Pumpcart

Therapeutic category	Auto-created by Agence nationale de sécurité du médicament — Disponibilité scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Verified timeline regulator events

🇫🇷 22 May 2026

medium reported

🇫🇷 18 May 2026

Shortage resolved

🇳🇱 10 Apr 2026

medium reported

🇫🇷 2 Apr 2026

medium reported

🇫🇷 1 Apr 2026

medium reported

🇳🇱 19 Mar 2026

medium reported

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.